Current post-operative care methods for skin grafts and burns involve the application of bandages, administration of vitamins and topical agents to the skin, and protection from sunlight. One company has developed a proprietary solution that may help to speed up the wound healing process while killing off infectious pathogens. PuriCore, a life sciences company that specializes in developing various types of skin solutions, has been performing randomized clinical trials with a product called Vashe Wound Therapy.
Vashe Wound Therapy is a medical device designed to support the wound healing process. The treatment has been used successfully and without any adverse side effects in more than 100,000 treatments, and is proving to an effective and economical alternative to common wound irrigation solutions.
The clinical trials were conducted by the Co-Director of the Arizona Burn Center of the Maricopa Medical Center in Phoenix, Arizona and results show that the treatment is just as effective as the 5% Sulfamylon® solution, a synthetic agent that is commonly used for the post-operative care of grafts for burns. Infection rates for the Vashe Wound Therapy and the Sulfamylon® solution were equivalent, but Vashe Wound Therapy boasts a greater than 50% cost savings.
Dr. Foster points out that, “Vashe Wound Therapy is an exciting new alternative technology that demonstrates clinical efficacy for post-operative skin graft irrigation while offering significant overall cost savings…this trial also suggests that Vashe has further potential for pain improvement opportunities.”
PuriCore’s CEO Greg Bosch also indicates that the clinical results prove that Vashe Wound Therapy is very effective for wound care and offers an additional boost to the body’s own defense system, making it much easier for the body to heal after burns or different types of surgery. The treatment is biocompatible, non-mutagenic and non-cytotoxic, and offers a safe and effective alternative to many solutions used to treat infected wounds and post-operative surgical sites.